NextCure
Yahoo Finance • 25 days ago
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avere Therapeutics. Click her... Full story
Yahoo Finance • last month
Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict
(RTTNews) - Today's top gainers in the biotech space include NextCure, ahead of its planned merger with a private company that will create a newly branded public entity; Basel Medical, which recently regained Nasdaq compliance; and Outlook... Full story
Yahoo Finance • last month
NextCure And Avere Therapeutics Announce Merger To Advance Oral IL-23 Therapy; Stock Up
(RTTNews) - NextCure, Inc. (NXTC) has entered into a definitive all-stock merger agreement with privately-held Avere Therapeutics, Inc., a biotech firm focused on oral therapies for IL-23 driven inflammatory diseases. The combined company... Full story
Yahoo Finance • 3 months ago
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Nex... Full story
Yahoo Finance • 4 months ago
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and... Full story
Yahoo Finance • 4 months ago
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in... Full story
Yahoo Finance • 5 months ago
NextCure GAAP EPS of -$19.65
* NextCure press release [https://seekingalpha.com/pr/20426620-nextcure-provides-business-update-and-reports-full-year-2025-financial-results] (NXTC [https://seekingalpha.com/symbol/NXTC]): FY GAAP EPS of -$19.65. * Cash, cash equivale... Full story
Yahoo Finance • 9 months ago
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept (“POC”)data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund,... Full story
Yahoo Finance • 10 months ago
NextCure and Simcere expand SIM0505 trial to the U.S.
* NextCure (NASDAQ:NXTC [https://seekingalpha.com/symbol/NXTC]) and Simcere Zaiming on Thursday said [https://seekingalpha.com/pr/20268668-nextcure-and-simcere-zaiming-announce-expansion-of-ongoing-phase-1-trial-of-sim0505-cdh6-adc]that... Full story
Yahoo Finance • 10 months ago
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nex... Full story
Yahoo Finance • 11 months ago
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, toda... Full story
Yahoo Finance • last year
NextCure GAAP EPS of -$11.29
* NextCure press release [https://seekingalpha.com/pr/20194108-nextcure-provides-business-update-and-reports-second-quarter-2025-financial-results] (NASDAQ:NXTC [https://seekingalpha.com/symbol/NXTC]): Q2 GAAP EPS of -$11.29. * Cash, c... Full story
Yahoo Finance • last year
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today... Full story
Yahoo Finance • last year
NextCure announces 1-for-12 reverse stock split effective July 14
NextCure, Inc. (NASDAQ:NXTC), currently trading at $0.45 with a market capitalization of $12.62 million, announced Thursday that its board of directors has approved a one-for-twelve reverse stock split of its common stock. The reverse stoc... Full story
Yahoo Finance • last year
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Init... Full story
Yahoo Finance • last year
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented... Full story
Yahoo Finance • last year
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, toda... Full story
Yahoo Finance • last year
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the sec... Full story
Yahoo Finance • 3 years ago
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-r... Full story
Yahoo Finance • 3 years ago
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modeling Update for ongoing Phase 1a clinical trial is ex... Full story